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Abstract 
Oral squamous cell carcinoma (OSCC) is the 7th most common malignancy and the 9th most frequent cause of 
cancer death in Europe. Within Europe, Hungary has one of the highest rates of OSCC incidence and mortality. 
Thus, there is an urgent need to improve early detection. Saliva, as a readily available body fluid, became an 
increasingly important substance for the detection of biomarkers for many diseases. Different research groups 
have identified salivary biomarkers specific for OSCC for different countries. In this study, saliva samples of 
Hungarian OSCC patients were studied in order to discover disease- and perhaps region-specific biomarkers. 
LC/MS/MS analysis on a linear ion trap-Orbitrap mass spectrometer was used for qualitative and quantitative 
salivary protein profiling. More than 500 proteins were identified from saliva by shotgun proteomics. The up- 
and downregulated proteins in the saliva of patients with OSCC highlighted the importance of protein-protein 
interaction networks involving the immune system and proteolysis in disease development. Two potential 
biomarkers from our shotgun analysis and a third candidate reported earlier by a Taiwanese group were further 
examined by ELISA on a larger reference set of samples. Resistin, a biomarker reported in Taiwan but not 
validated in our study, highlights the necessity of application of standardized analysis methods in different 
ethnic or geographical populations in order to identify biomarkers with sufficient specificity and sensitivity.  
 
Introduction 
The oral cavity is the most frequent site of head and neck cancers, developing predominantly as oral cavity 
squamous cell carcinomas (OSCC) in the upper aerodigestive epithelium [1,2]. The three major recognized risk 
factors of OSCC are tobacco, and alcohol-consumption and poor oral hygiene [3–5]. OSCC mortality rates 
reflect the different consumption patterns of alcohol and tobacco in European countries [6]. Annually more than 
300,000 new patients are diagnosed with OSCC worldwide. The disease is associated with poor prognosis and 
high mortality mainly due to late diagnosis because of the lack of reliable early diagnostic markers [7]. 
Mortality rate from OSCC is about 10-fold higher for men than for women. However, female OSCC incidence 
increased dramatically in the last decade. In addition, a rising tendency was observed in younger patient cohorts 
[8]. In contrast to other European countries where the mortality rates of OSCC started to decline, unfavorable 
incidence and mortality figures remained exceedingly high in Hungary since the 1970s’ representing a major 
public health challenge [9]. 
Development of cancer diagnostic tools with sufficiently high sensitivity and specificity is required to enable 
early detection of OSCC [10]. Recent treatment strategies of OSCC patients are based on traditional stage-
predicting indices and histological grading [11]. Unfortunately, these predictors are relatively subjective and 
unreliable because tumors with same staging and grading may respond to therapy differently. Thus, improving 
the diagnostic methods is required. A potential way of improving our diagnostic tools is to perform in-depth 
salivary analyses to discover and to assess biochemical and immunological markers in the saliva for early oral 
cancer diagnosis [12-13]. Biomarkers identified in the last decades in biological fluids can be linked to 
carcinogenesis and may serve as prognostic factors and saliva is a new clinical biomarker source that can be 
easily collected by non-invasive means [14-18]. Since there is direct contact between saliva and the oral 
lesion(s) disease-related concentration changes of saliva ingredients may provide as good or better clues than 
serum samples [19]. More than 3700 salivary proteins have been identified by several research groups [20,21]. 
Many proteins were declared potential salivary biomarkers of OSCC in different countries [22–24]. In this 
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study, we present a two-stage approach for the discovery of candidate OSCC-specific salivary biomarkers in the 
Hungarian population. LC/MS/MS analysis using ultra-Performance Liquid Chromatography (UPLC) coupled 
to a linear ion trap-Orbitrap hybrid tandem mass spectrometer was applied for qualitative and quantitative 
salivary protein profiling. Selected proteins, based on the shotgun analysis of a few randomly selected samples, 
were further investigated by ELISA on a reference set of samples.  
 
Materials and Methods 
Patients and saliva collection  
Donor enrollment, sample collection and processing were conformed to the principles of the Helsinki 
Declaration. Ethical approval was obtained from the University of Debrecen Ethics Committee (No. 3385-2011) 
and all subjects provided written informed consent. Clinical examinations were performed by dental surgeons 
from the Faculty of Dentistry, University of Debrecen. Adult patients (>18 yrs) with histology-proven OSCC 
were recruited into the study. Saliva samples were collected before starting any anti-tumor therapy. Age-
matched controls (MCTL) were consecutive patients and young controls (YCTL) were medical students 
admitted to the Faculty of Dentistry for regular dental checkup. Exclusion criteria included children (</= 18 
yrs), pregnancy and breast feeding, diabetes mellitus, human papillomavirus infection, human 
immunodeficiency virus infection, autoimmune and immunodeficiency disorders and cancer other than OSCC. 
Unstimulated saliva samples were collected from 43 donors between 9 a.m. and 11 a.m. at the Faculty of 
Dentistry, University of Debrecen (collection between 2013.05.09-2016.02.29.). The test set contained 3 
randomly selected samples from patients with OSCC and controls for proteomic analysis, whereas the reference 
set contained samples from 20 patients with OSCC (mean age: 57 year), 6 young (mean age: 24,5 year) and 11 
age-matched CTLs (mean age: 59 year) for biomarker verification. Saliva samples were kept on ice during 
collection and were filtered using 5 μm pore size Millipore SLSV025LS syringe filters (Merck, Billerica, MA, 
USA). The filtered saliva was aliquoted and immediately placed to -70°C until further use.  
 
Sample preparation for mass spectrometry 
Filtered saliva was dried in speed-vac and redissolved in 25 mM pH 8.5 ammonium bicarbonate buffer. Total 
protein concentration of salivary samples was measured using the Bradford method [25]. Following 
denaturation with 8 M urea, all samples were reduced with 10 mM dithiothreitol (Bio-Rad, Hercules, CA, 
USA) in ammonium bicarbonate buffer. Then samples were alkylated with 20 mM iodoacetamide (Bio-Rad, 
Hercules, CA, USA) in ammonium bicarbonate buffer and diluted with 25 mM ammonium bicarbonate (Sigma, 
St. Louis, MO, USA) in order to reduce the urea concentration to 1 M. Each sample was digested by MS grade 
modified trypsin (ABSciex, Framingham, MA, USA) in 1:25 enzyme to protein ratio (w/w) at 37oC, overnight. 
The digested samples were dried in speed-vac and redissolved in 0.1% formic acid. The digests were desalted on 
Pierce C18 Tips (Thermo Scientific, West Palm Beach, FL, USA) and the eluates were dried and stored at -70°C 
until mass spectrometry analysis. 
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Mass spectrometry analysis 
Tryptic digests representing 2 μg total protein were analyzed by LC-MS/MS using a Waters nanoAcquity UPLC 
on-line coupled to a linear ion trap-Orbitrap hybrid tandem mass spectrometer (Orbitrap Elite, Thermo 
Scientific) operating in positive ion mode. After trapping at 3% B (Waters Symmetry C18 180 μm x 20 mm 
column, 5 μm particle size, 100 Å pore size; flow rate: 10 μl/min), peptides were fractionated using a linear 
gradient of 3 to 40% B in 100 min (Waters BEH C18 75 μm x 250 mm column, 1.7 μm particle size, 300 Å pore 
size; solvent A: 0.1% formic acid/water, solvent B: 0.1% formic acid / 5% dimethyl sulfoxide / acetonitrile; 
flow rate: 400 nl/min).  Data acquisition was carried out in a data-dependent fashion, the 10 most abundant, 
multiply charged ions were selected from each MS survey (m/z: 380-1600, resolution: 60000, acquired in profile 
mode) for MS/MS analyses. CID analyses were performed in the linear ion trap (normalized collision energy: 
35). Dynamic exclusion was enabled (exclusion time: 30 s).   
 
Protein identification 
Peak lists generated from the MS/MS data by the ‘PAVA’ software [26] were searched against the human subset 
of the Uniprot database (downloaded 06/10/2014; 136245 target sequences concatenated with a randomized 
sequence for each entry) using the ProteinProspector search engine (v.5.10.9.). Search parameters: enzyme: 
trypsin with maximum 1 missed cleavage site; fixed modification: carbamidomethyl (Cys); variable 
modifications: acetylation (protein N-terminus), oxidation (Met), pyroglutamic acid formation (N-terminal Gln) 
allowing up to 2 variable modifications per peptide; mass accuracy: 5 ppm and 0.6 Da for precursor and 
fragment ions (both monoisotopic), respectively. The following acceptance criteria were applied: score>22 and 
15, and E-value<0.01 and 0.05 for protein and peptide identifications, respectively. The false positive rates of 
the identified proteins and peptides were less than 1%. Relative abundance of individual proteins was estimated 
by spectral counting: the number of identifications per protein (PSMs) was normalized to the total number of 
identifications, then these relative spectral counts were compared across the different samples.  
Functional analyses were performed in case of proteins with at least three unique peptide identifications. For the 
calculation of the OSCC/control ratio those proteins were considered which were identified with at least 3 
unique peptides in at least two out of three samples in either the control or the OSCC group.  
 
Validation of the candidate biomarkers using ELISA 
All saliva samples from patients with OSCC and controls were analyzed in duplicate with quantitative ELISA. 
The ELISA kit for heparin cofactor 2 (#Cat. number: LS-F13221) was purchased from LifeSpan Biosciences 
(Seattle, WA, USA), for resistin (#Cat. number: KHP0051) from Thermo Fisher Scientific (West Palm Beach, 
FL, USA) and for complement c5 (#Cat. number: ab125963) from Abcam (Branford, Connecticut, USA). The 
concentration of the studied proteins in saliva was measured by sandwich enzyme-linked immunosorbent assay 
method according to the instruction provided by the vendor of each kit. Absorbance was measured at 450 nm 
and concentrations were calculated based on the recorded 7-point calibration curves. 
First, the variation coefficient of the parallel measurements was calculated and those data having more than 25 
CV % value were excluded from statistical analysis.  
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Bioinformatics 
The cluster analysis was carried out with Cluster 3.0 (http://cluster2.software.informer.com/) using the C 
Clustering Library version 1.52 and the heat map was created with Java TreeView version 1.1.6r4 [27].  
The protein-protein interaction network of salivary proteins was generated using String version 10.5 [28,29] 
applying default settings and medium stringency. After the generation of networks the enriched GO terms 
provided by the software were also examined. 
The statistical analysis of ELISA data was performed using the Mann–Whitney U test and the two sample T-test 
in order to compare the protein concentrations between groups. Those data were considered significantly 
different where the p value was p < 0.05. 
 
Results and Discussions 
 
Demographic and clinical characteristics of patients with OSCC  
Among the included 17 patients 13 were males and 4 females between the age of 44-73 yrs. In six cases the 
tumor developed in the tongue (T), in 4 cases in the floor of the mouth (F) and in 3 cases it was detected in the 
gingival (G) region. In 4 cases the tumor development showed multiple localization, in 2 patients the tumor 
developed in the tongue and either in the floor of the mouth or the gingival region, while in another 2 patients 
the tumor development was detected in the tongue, in the floor of the mouth and also in the gingival region. 
Eight patients were discovered in early tumor development stage (stage I.: 5, stage II.: 3) and 9 patients were 
diagnosed with advanced tumors (stage III.: 4 and stage IV.: 5). There were six well differentiated (W), 7 
moderately differentiated (M) and 4 poorly differentiated (P) OSCC samples (Table 1). 
 
Shotgun proteomic analysis of saliva samples 
Three randomly selected samples from patients with OSCC and matched controls respectively, were subjected 
to shotgun proteomics analysis. More than 500 proteins were identified from salivary samples. For protein 
quantification spectral counting was used and the ratios of OSCC:CTL protein quantities have been determined.  
Detailed information of the identified proteins is presented in Supplementary Table 1. 
The proteins with at least 3 unique sequences and with at least 2 fold change value (OSCC/CTL ratio <0.5 or 
>2) were subjected to further examination. A cluster analysis was carried out and a heat map was generated to 
visualize the changes in protein amount in CTL and OSCC samples (Figure 1). Based on cluster analysis the 
protein levels can discriminate the OSCC group from the CTL group. Proteins were classified as salivary 
proteins or proteins being present in saliva under normal conditions and as acute phase proteins (Table 2). For 
protein classification the Uniprot and the Sys-BodyFluid databases were used, the latter contains more than 
10,000 proteins of different body fluid proteomes [30]. In addition, some proteins were classified as salivary 
proteins based on literature data [21, 31–35].  
2 proteins, the cytochrome c and mucin-7 were only present in the CTL samples and 6 proteins, the complement 
factor H (CFH) and C5 (C5), corticosteroid binding globulin (SERPINA6), heparin cofactor 2 (SERPIND1), 
apolipoprotein E (APOE) and serum paraoxonase/arylesterase 1 (PON1), were only present in the OSCC 
samples (Table 3).  
 
A
cc
ep
te
d 
A
rt
ic
le
FEBS Open Bio (2018) © 2018 The Authors. Published by FEBS Press and John Wiley & 
Sons Ltd. 
Functional analysis of salivary proteins 
It was observed that the level of apolipoproteins, components of the complement system, proteinases, proteinase 
inhibitors, components of the coagulation cascade is upregulated indicating a change in proteolysis most 
probably associated with the interrelated coagulation cascade-complement activation processes. In the same 
time the level of proteins having role in metabolism and host defense was downregulated showing extensive 
cancer-related changes (Table 2). For a more detailed functional analysis of the differentially expressed proteins 
gene ontology (GO) analysis was performed; the Biological Process, Molecular Function and Cellular 
Localization according to GO (http://www.geneontology.org/) was examined. First, the network of 
differentially expressed proteins was generated using String version 10.5 [28,29] followed by GO enrichment 
analysis provided by String. The network of downregulated proteins contained 35 proteins (nodes) and 27 
possible protein-protein interactions analyzed at medium stringency (Figure 2A). No biological function was 
enriched in the down-regulated proteins in this loosely connected network (Figure 2B), however 7 out of 35 
downregulated proteins are metabolic enzymes participating mainly in carbohydrate metabolism and 10 proteins 
out of 35 have a role in defense. The upregulated 45 proteins show a highly interconnected protein-protein 
interaction network with 400 interactions analyzed at medium stringency (Figure 2C). The enriched functions 
indicate active regulatory mechanisms implicating the immune system, lipid metabolism, plasminogen 
activation, antioxidant activity and inhibition of enzymatic activities (Figure 2D). Regarding localization of up- 
or downregulated proteins, all are mainly extracellular proteins according to GO (Figure 2B and 2D), but a part 
of the upregulated proteins originate from lipid particles or platelet alpha granules indicating the presence of a 
possibly cancer-induced complex process involving systemic mechanisms.  
In order to get more insights into the changes associated with OSCC a literature search was performed to see 
which proteins have been associated with oncogenesis. Most of the proteins were already associated with 
OSCC, and 32 proteins were identified to be present in saliva in this pathological condition.  
Complement C4B (C4B), complement factor B (CFB), complement C3 and alpha-1-antitrypsin were shown to 
be associated with the risk of developing OSCC according to a targeted proteomics study [36]. The level of 
apolipoproteins A and E, PON1, inter-alpha-trypsin inhibitor heavy chain H1, H2 and H4, kininogen 1, protein 
AMBP, nucleobinding-2, SERPIND1 and SERPINA6 were found to be upregulated in OSCC in shotgun 
proteomics experiments carried out on saliva samples [23]. The presence of ApoE was related to the increased 
invasion potential of OSCC [37]. 
The alpha-1-acid glycoprotein, alpha-1B glycoprotein, alpha amylase, beta-2-glycoprotein, carbonic anhydrase 
1, cystatin-SA, hemopexin, phosphoglycerate kinase and serum albumin were identified as potential salivary 
markers of OSCC [14,16,22].  
Some of the proteins found to be differentially expressed in our study such as fibrinogen alpha, beta and gamma 
chains, haptoglobin, SERPINB5, retinol binding protein 4 and ceruloplasmin, were shown to be plasma markers 
of OSCC while the presence of integrin alpha-M and fibronectin FN1 was demonstrated in the OSCC tissue 
[12,38-43]. 
In case of 36 proteins no association with OSCC was found so far (Table 2). Angiotensinogen and plasminogen 
themselves were not found to be associated with OSCC but the plasminogen activator system was shown to be a 
predictive marker for early OSCC and by bioinformatics analysis the angiotensin converting enzymes were 
associated with malignant epithelial neoplasia characteristic for OSCC [44,45]. In case of 6 proteins not the 
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protein from our list, but another protein from the same family was already demonstrated to be differentially 
expressed in OSCC (Table 2). In case of SERPINB5 there are contradictory data; in our study the level of 
SERPINB5 was found to be elevated in OSCC, however the SERPINB5 and different forms of SERPINS from 
clade B were found by other groups to be downregulated in OSCC on mRNA level and higher SERPINB5 
levels were found to correlate with better prognosis of patients with oral cancer [46,47].  
Plasma protease C1 inhibitor (SERPING1), antithrombin III and fibronectin were found to play a role in 
carcinogenesis but their implication in oral cancer, especially in OSCC has not been demonstrated yet [48,49]. 
The complement factor H was previously identified in lung adenocarcinoma and cutaneous squamous cell 
carcinoma, but not in OSCC [50,51] and Apo B100 was found in serum of patients with head and neck 
squamous cell carcinoma [52]. No data were found on the presence of complement C5 and mucin-7 in cancer, 
however other components of the complement system and other forms of mucins were all identified in different 
forms of cancer and in OSCC as well [36, 53].  
As for the involvement of cytochrome c, it was shown that the HIF-1alpha-dependent suppression of hypoxia-
induced apoptosis in OSCC happens through the inhibition of cytochrome c release [54].  
 
Examination of the level of selected proteins by ELISA 
Many of the studies published in the scientific literature are based on shotgun proteomic experiments. Only few 
of the proteins listed in Table 2 were verified or validated either using SRM-based targeted or antibody-based 
methods. Considering the proteins present only in OSCC based on our shotgun experiments, the data presented 
in the literature, and the availability of antibodies, SERPIND1 and C5 were selected for further studies. In order 
to test the utility of potential biomarkers identified in Asia for a European population, resistin reported to be a 
potential biomarker for OSCC in Taiwan [23] was also selected.  
The concentrations of C5, SERPIND1 and resistin were examined in the saliva of patients with OSCC, age-
matched and young controls using quantitative sandwich ELISA kits (Figure 3). In case of C5 the difference 
was significant but only when young controls and patients with OSCC or young controls and age-matched 
controls were compared indicating that the level of C5 was age-dependent or it was influenced by other factors. 
One such factor can be the inflammatory status related to poor oral hygiene often observed in the middle-aged 
and elderly population in Hungary [55]. This means that despite the differential expression of C5 in the OSCC 
group, the level of C5 does not discriminate between the target age-matched control and diseased group and 
hence it cannot be used as a biomarker for OSCC.  
In case of resistin and SERPIND1 no significant differences were found between the groups. Resistin was not 
up- or downregulated according to our shotgun experiments and did not show significant differences in the 
ELISA experiments either. In case of SERPIND1 one possible explanation of the disagreement between the 
shotgun proteomics and ELISA data can be that the low number of samples (3 for each group) tested by shotgun 
proteomics and the high individual variation of the saliva samples collected from the patients may lead to false 
positive results. This outcome highlights the importance of validation of the shotgun proteomics data on larger 
patient cohorts to decrease the false positivity of biomarker identifications.. In a two-stage experimental 
approach, starting with a shotgun proteomics experiment, the level of resistin was found to be significantly 
higher in saliva samples of OSCC patients compared to controls. However, following ELISA assays showed 
that the median values in the OSCC group were only slightly elevated compared to the control group [23]. In the 
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same study SERPIND1 was not validated but was shown to be upregulated in the saliva samples of patients with 
OSCC. In our study a similar experimental setup was applied; in the shotgun experiment the level of SERPIND1 
was higher but the level of resistin did not change markedly in the OSCC group and the validation of 
SERPIND1 and resistin show that none of them turned to be useful potential biomarkers. The fact that resistin 
was identified as a biomarker for OSCC in Taiwan but not in Hungary gives further evidence for the importance 
of regional studies highlighted in our previous work [56]. 
 
Conclusions 
Global analysis of salivary samples from patients with OSCC and controls contribute to the better understanding 
of the disease, including the interaction of tumor cells with their environment and the influence of cancer lesion 
on salivary protein ecology. Salivary proteins, characterizing patients with OSCC in this study highlighted the 
importance of networks involving the immune system and proteolysis in this disease. Six proteins were only 
detected in OSCC samples by proteomic analyses and two of them were further examined using ELISA assay 
but none of the proteins turned to be a potential biomarker in OSCC in our study group. The fact that resistin 
was shown to be a possible biomarker in Taiwan but not in our study highlights the importance of regional or 
population-tailored studies. 
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Figure legends 
 
Figure 1. Cluster analysis and heat map of proteins identified in CTL and OSCC groups. The relative 
peptide count (%), characteristic for each sample is shown. 
Figure 2. The protein-protein interaction network and functional classification of up- and downregulated 
proteins in OSCC The network of downregulated (A) and upregulated (C) proteins in OSCC displayed by 
String 10.4 using default settings and medium stringency. Each node represents a protein and the edges 
represent protein-protein interactions based on different levels of evidences collected by String.  The enrichment 
table of GO terms calculated by String in case of downregulated (B) and upregulated (D) proteins is shown 
indicating the number of the proteins belonging to each term and the false discovery rate value calculated by 
String.  
Figure 3. Examination of potential salivary biomarkers using ELISA assay The concentration of 
SERPIND1 (A), resistin (B) and complement C5 (C) proteins in the saliva samples collected from OSSC 
patients (OSCC), young controls (YCTL) and age-matched controls (MCTL). The p value is indicated, * refers 
to p<0.05. 
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Table 1. Demographic and clinical characteristics of OSCC patients. In case of each patient the gender, age 
tumor localization, TNM classification, stage and stage of differentiation is given. M is for male, F for female. 
Regarding tumor localization, T is for tongue, G is for gingiva, F is for floor of the mouth. The W is for well 
differentiated, M is for moderately differentiated and P is for poorly differentiated tumors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Patient 
code 
Gender 
Age 
(year) 
Tumor 
localization 
TNM 
classification 
Tumor 
stage 
Stage of 
differentiation 
1 M 73 T T2N1M0 III W 
2 F 69 G T4N0M0 IV W 
3 F 67 F T4N2M0 IV W 
4 M 52 T;G;F T4N1M0 IV M 
5 M 57 T T3N0M0 III W 
6 F 59 T T1N0M0 I W 
7 M 67 F T1N0M0 I W 
8 F 50 T T2N0M0 II M 
9 M 52 T;G T2N2M0 IV M 
10 M 48 T T1N0M0 I M 
11 M 64 T T2N0M0 II P 
12 M 44 G T4N1M0 IV M 
13 M 44 T;F T3N0M0 III M 
14 M 60 F T2N0M0 II M 
15 M 49 T;G;F T3N1M0 III P 
16 M 47 G T1N0M0 I P 
17 M 64 F T1N0M0 I P 
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Table 2. List of proteins with at least two fold change between OSCC and CTL groups. The Uniprot 
protein ID, the protein name and function is presented. The representative identification and quantification data, 
the number (#) of unique peptides, the sequence coverage (% Cov) and the OSCC/CTL ratio are given in each 
case. Classification indicating salivary (S) or acute phase (A) proteins is presented. The type of sample from 
patients with OSCC where the protein was identified is also listed. * indicates that not the protein itself, but 
another close family member of it was already found in OSCC. NI denotes proteins not identified in OSCC yet. 
 
Protein 
ID 
Protein Name 
# unique 
peptide 
% 
Cov 
OSCC/
CTL 
ratio 
Classification Function 
Type of 
OSCC 
sample 
O60218 Aldo-keto reductase 
family 1 member B10 
5 17 0,10 S metabolic 
enzyme 
saliva* [23] 
 
P02763 Alpha-1-acid 
glycoprotein 1 
8 37 3,14 AS immune 
response, 
transport saliva [16] 
P01011 Alpha-1-
antichymotrypsin 
12 31 3,29 AS protease 
inhibitor NI 
P01009 Alpha-1-antitrypsin 25 62 3,70 S protease 
inhibitor saliva [36] 
P04217 Alpha-1B-
glycoprotein 
12 39 3,25 S immune 
response saliva [16] 
P02765 Alpha-2-HS-
glycoprotein 
7 26 2,70 AS protease 
inhibitor, 
immune 
response, 
transport 
NI 
 
P01023 Alpha-2-
macroglobulin 
54 51 2,16 S protease 
inhibitor NI 
P04745 Alpha-amylase 1 42 83 0,21 S metabolic 
enzyme saliva [14] 
P01019 Angiotensinogen 7 18 8,50 AS renin-
angiotensin 
system NI 
P01008 Antithrombin-III 7 22 2,08 AS protease 
inhibitor, 
blood 
coagulation NI 
P02647 Apolipoprotein A-I 24 69 2,14 S lipid 
metabolism saliva [23] 
P02652 Apolipoprotein A-II 7 67 3,85 S lipid 
metabolism saliva [23] 
P06727 Apolipoprotein A-IV 5 16 3,55 S lipid 
metabolism saliva [23] 
P04114 Apolipoprotein B-100 42 13 8,12 S lipid 
metabolism NI 
P02649 Apolipoprotein E 4 18 only in 
OSCC 
S lipid 
metabolism 
saliva [23] 
P17213 Bactericidal 
permeability-
increasing protein 
4 12 0,24 S immune 
response 
NI 
P02749 Beta-2-glycoprotein 1 12 44 3,02 S lipid 
metabolism, 
blood 
coagulation saliva [22] 
P61769 Beta-2-microglobulin 5 57 0,46 S immune NI 
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response 
Q96DR5 BPI fold-containing 
family A member 2 
11 41 0,49 S immune 
response, 
defense NI 
Q14CN2 Calcium-activated 
chloride channel 
regulator 4 
5 8 0,23 S transport 
NI 
P27482 Calmodulin-like 
protein 3 
6 64 0,37 S metal 
binding, 
chaperone NI 
P27797 Calreticulin 4 19 0,37 S chaperone NI 
P00915 Carbonic anhydrase 1 6 34 8,55 S metabolic 
enzyme, 
acid-base 
balance saliva [22] 
P00450 Ceruloplasmin 27 37 3,65 AS metal 
binding blood [39] 
O00299 Chloride intracellular 
channel protein 1 
7 34 0,31 S transport, 
cell cycle 
regulation NI 
P01024 Complement C3 84 61 2,77 AS immune 
response saliva [36] 
P0C0L5 Complement C4-B 32 25 6,69 AS immune 
response saliva [36] 
P01031 Complement C5 7 5 only in 
OSCC 
AS immune 
response 
NI 
B4E1Z4 Complement factor B 22 22 5,44 AS immune 
response saliva [36] 
P08603 Complement factor H 21 22 only in 
OSCC 
AS immune 
response 
NI 
P05156 Complement factor I 3 7 6,42 AS immune 
response NI 
P22528 Cornifin-B 6 79 0,45 S cornification NI 
P08185 Corticosteroid-binding 
globulin 
4 15 only in 
OSCC 
AS protease 
inhibitor saliva [23] 
P04080 Cystatin-B 6 86 0,39 S protease 
inhibitor NI 
P01034 Cystatin-C 7 43 0,33 S protease 
inhibitor NI 
P09228 Cystatin-SA 13 69 0,35 S protease 
inhibitor saliva [14] 
P99999 Cytochrome c 4 32 0,00 A electron 
transport 
chain, 
apoptosis tissue [54] 
Q02413 Desmoglein-1 8 12 0,40 S desmosome 
component 
NI 
P61916 Epididymal secretory 
protein E1 
4 33 0,30 S lipid 
metabolism, 
cholesterol 
transport NI 
Q01469 Fatty acid-binding 
protein, epidermal 
12 79 0,49 S lipid 
metabolism 
saliva* [23] 
P02671 Fibrinogen alpha chain 11 13 2,67 AS blood 
coagulation blood [40] 
P02675 Fibrinogen beta chain 20 49 2,91 AS blood blood [40] 
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coagulation 
P02679 Fibrinogen gamma 
chain 
18 48 2,43 AS blood 
coagulation blood [40] 
B7ZLE5 FN1 protein 24 17 5,73 S cell adhesion tissue [43] 
P00738 Haptoglobin 29 67 2,61 AS hem binding blood [38] 
P69905 Hemoglobin subunit 
alpha 
11 92 3,37 S oxygen 
transport saliva* [23] 
P68871 Hemoglobin subunit 
beta 
17 94 4,41 S oxygen 
transport saliva* [23] 
P02790 Hemopexin 20 52 2,41 AS hem binding saliva [16, 
22] 
P05546 Heparin cofactor 2 8 17 only in 
OSCC 
A blood 
coagulation 
saliva [23] 
Q9Y6R7 IgGFc-binding protein 52 17 0,49 S immune 
response NI 
P11215 Integrin alpha-M 6 9 2,01 S immune 
response tissue [41] 
P19827 Inter-alpha-trypsin 
inhibitor heavy chain 
H1 
8 14 3,76 S protease 
inhibitor 
saliva [23] 
P19823 Inter-alpha-trypsin 
inhibitor heavy chain 
H2 
10 18 11,23 S protease 
inhibitor 
saliva [23] 
Q14624 Inter-alpha-trypsin 
inhibitor heavy chain 
H4 
13 22 5,33 S protease 
inhibitor 
saliva [23] 
P02538 Keratin, type II 
cytoskeletal 6A 
21 39 0,44 S cytoskeleton 
NI 
P01042 Kininogen-1 11 18 2,89 S protease 
inhibitor, 
blood 
coagulation saliva [23] 
P61626 Lysozyme C 7 54 0,47 S host defense NI 
P40926 Malate dehydrogenase, 
mitochondrial 
4 17 0,37 S metabolic 
enzyme 
NI 
Q8TAX7 Mucin-7 4 12 0,00 S host defense NI 
P80303 Nucleobindin-2 8 26 0,32 S metal 
binding saliva [23] 
Q6UX06 Olfactomedin-4 7 20 0,47 S cell adhesion NI 
P36871 Phosphoglucomutase-
1 
6 13 0,08 S metabolic 
enzyme NI 
Q96G03 Phosphoglucomutase-
2 
5 11 0,40 S metabolic 
enzyme NI 
P00558 Phosphoglycerate 
kinase 1 
10 33 0,44 S metabolic 
enzyme saliva [22] 
P36955 Pigment epithelium-
derived factor 
4 12 7,17 S tumor 
development
, 
angiogenesis NI 
P05155 Plasma protease C1 
inhibitor 
8 21 5,95 S protease 
inhibitor, 
blood 
coagulation NI 
P00747 Plasminogen 9 17 5,11 AS blood 
coagulation NI 
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P02760 Protein AMBP 6 23 5,41 S protease 
inhibitor, 
host defense saliva [23] 
O60888 Protein CutA 3 33 0,43 S metal 
binding, 
enzyme 
binding NI 
P02753 Retinol-binding 
protein 4 
5 24 2,54 S protease 
inhibitor, 
host defense blood [42] 
Q9NQ38 Serine protease 
inhibitor Kazal-type 5 
11 13 0,32 S lipid 
metabolism 
NI 
P36952 Serpin B5 4 14 2,63 S tumor 
suppressor blood [12] 
P02768 Serum albumin 71 84 2,53 S transport saliva [22] 
P27169 Serum 
paraoxonase/arylestera
se 1 
9 37 only in 
OSCC 
A detoxificatio
n 
saliva [23] 
P35326 Small proline-rich 
protein 2A 
6 79 0,29 S cornification 
saliva* [23] 
Q6UWP8 Suprabasin 12 33 0,05 S cell 
proliferation 
NI 
P62328 Thymosin beta-4 5 64 0,42 S actin 
binding, cell 
proliferation NI 
O60235 Transmembrane 
protease serine 11D 
3 10 0,20 S protease, 
host defense 
NI 
P68363 Tubulin alpha-1B 
chain 
4 12 0,40 S microtubule 
component 
saliva* [23] 
O75083 WD repeat-containing 
protein 1 
7 19 0,13 S cell 
migration 
NI 
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Table 3. Proteins identified only in the OSCC or CTL groups.  
Protein ID1 Protein name Gene name Function Presence 
Reference to 
previous studies  
P02649 Apolipoprotein E APOE lipid metabolism  only OSCC 
identified in 
saliva of patients 
with OSCC [23] 
P01031 Complement C5 C5 
innate immune 
response, complement 
component 
only OSCC 
not identified in 
cancer yet  
P08603 Complement factor H CFH 
innate immune 
response, complement 
component 
only OSCC 
identified in other 
forms of cancer 
but not in OSCC 
[50,51] 
P08185 
Corticosteroid-binding 
globulin 
SERPINA6 protease inhibitor only OSCC 
identified in 
saliva of patients 
with OSCC [23] 
P05546 Heparin cofactor 2 SERPIND1 blood coagulation only OSCC 
identified in 
saliva of patients 
with OSCC [23] 
P27169 
Serum 
paraoxonase/arylesterase 1 
PON1 detoxification  only OSCC 
identified in 
saliva of patients 
with OSCC [23] 
P99999 Cytochrome c CYCS 
electron transport chain, 
its release from 
mitochondria initiates 
apoptosis 
only Ctrl 
its release was 
inhibited in 
OSCC [54] 
Q8TAX7 Mucin 7 MUC7 
antibacterial activity, 
host defense 
only Ctrl 
not identified in 
cancer yet  
 
Based on 1http://www.uniprot.org/. 
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